BIOCAPTIVA key facts
as of Oct 2026- Developer of sample capture and processing technologies designed to improve the quality and reliability of biomarker analysis.
- BIOCAPTIVA is valued at approximately $13.8M as of Oct 2026 (last reported valuation).
- It has raised $8.5M; the latest was Later Stage VC ($2.1M) in Feb 2026.
- Notable investors include Scottish Enterprise, Old College Capital, British Business Investments, University of Edinburgh Endowment, Archangel Investors — 7 tracked in total.
- Status: Privately Held (backing).
BIOCAPTIVA's last reported valuation, Feb 2026. Nothing priced has surfaced since.
- ·Watch BIOCAPTIVA: the Monday email on marks, rounds and moves
BIOCAPTIVA funding rounds
No funding rounds for BIOCAPTIVA are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
BIOCAPTIVA valuation
BIOCAPTIVA's last reported valuation was $13.8 million in Feb 2026. No priced round, secondary trade or fund mark has surfaced since.
BIOCAPTIVA investors
7 investors are on record for BIOCAPTIVA, including Scottish Enterprise, Old College Capital, British Business Investments and University of Edinburgh Endowment.
About BIOCAPTIVA
Developer of sample capture and processing technologies designed to improve the quality and reliability of biomarker analysis. The company's platform offers surface binding polymer-based capture methods for circulating free DNA with enhanced stability and purity, enabling diagnostic laboratories, biotechnology companies and healthcare providers, to improve biomarker detection and analysis in clinical testing.
- Sector
- Healthcare
- HQ
- Edinburgh, United Kingdom
- Founded
- 2021
- Employees
- 10
- Website
- biocaptiva.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.